Surgical management for burns has been reported to effectively manage such cases via early excisions and grafting to enhance re-epithelization. However, the operation is very expensive and not be suitable for many patients, especially those suffering from extensive body burns across huge surface areas. Recombinant human granulocyte-macrophage colonystimulating factor has been validated to effectively manage severe burns, resulting in favorable outcomes and minimal or absent adverse events. Recombinant human granulocyte-macrophage colony-stimulating factor should be used for the management of such patients due to the favorable events that have been extensively reported among studies in the literature. Some of these events include reducing the healing time and increasing the rates of wound healing among burns patients, when compared to other treatment modalities. Additionally, various studies have also demonstrated that no significant adverse events are associated with it, adding to its efficacy in the management of deep burns. However, it should be noted that further research is still encouraged to further validate the current evidence, and to validate the effect on scarring. Further details are discussed within the manuscript.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.